Lifetime Citizen Portal Access — AI Briefings, Alerts & Unlimited Follows
Private lab and VA discuss RNA sequencing pilot for PTSD; VA supports study with cautions
Loading...
Summary
A private company and a House sponsor urged a VA pilot using RNA transcriptome analysis to improve PTSD diagnosis and monitoring; VA told the committee it supports studying RNA sequencing but raised concerns about several bill provisions and sought discussions on clinical use and protections.
A House subcommittee heard testimony from a private company promoting RNA transcriptome testing as an objective diagnostic and monitoring tool for PTSD and trauma‑related conditions, and VA officials said they support a study but want to work with the committee to resolve several bill provisions.
Representative Murphy, sponsor of the Veterans PTSD Screening Act (H.R. 3886), told the subcommittee that RNA sequencing assays can reveal markers of stress and inflammation that differ in individuals with PTSD. Murphy said a statutory pilot would help VA evaluate whether RNA‑based assays could supplement clinical assessments.
John Schmidt, chief executive officer of iXpress Genes, described a laboratory‑developed blood test called the trauma autoimmune indicator (TII) that reads RNA transcription and, he said, “identifies inflammation caused by trauma detectable before symptoms even surface.” Schmidt said the test is commercially available through his lab and that early partnerships with VA Birmingham produced promising results.
VA witnesses said the department “supports the proposed bill directing VA to conduct a study on RNA sequencing to diagnose PTSD” but identified concerns with several provisions and asked to provide technical assistance. Dr. Chappelle emphasized that VA would not want RNA tests used alone to deny care and said a holistic approach to PTSD diagnosis remains essential.
No committee action was taken. Members and witnesses emphasized that any pilot should include protections against using a single biomarker as the sole basis for care or benefits decisions and should include prospective validation with clear clinical endpoints and reporting requirements.
